Opus Genetics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Yun Zhong from Wedbush maintained a Buy rating on the stock and has a $8.00 price target.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Yun Zhong has given his Buy rating due to a combination of factors related to both Opus Genetics’ partnered drug and its internal gene therapy pipeline. He views FDA approval of the phentolamine ophthalmic solution for presbyopia as relatively low risk, and expects its favorable safety profile—especially the lower incidence of headaches and lack of retinal tear concerns versus some rivals—to support strong commercial uptake in a very large U.S. patient population.
He also highlights the company’s BEST1 gene therapy program as a key long‑term value driver, with upcoming Phase 1/2 data serving as an important catalyst and potential path toward a pivotal trial. Positive preclinical results and a clear plan to use retinal fluid resolution as an early efficacy signal provide confidence in the program’s clinical strategy, while milestone and royalty economics from partner Viatris add incremental non‑dilutive value. Taken together, these elements underpin his constructive outlook on IRD shares and support the Buy recommendation.
According to TipRanks, Zhong is an analyst with an average return of -6.3% and a 43.96% success rate. Zhong covers the Healthcare sector, focusing on stocks such as Ascendis Pharma, Wave Life Sciences, and BioMarin Pharmaceutical.
In another report released today, LifeSci Capital also reiterated a Buy rating on the stock with a $8.00 price target.